Andropause, androgen therapy and prostate safety

References

• Burris A S, Banks S M, Carter C S, Davidson T M, Sheris RJ. A long term prospective study of the physiological and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992; 13: 297–303
   PubMedGoogle Scholar
• Finkelstein J S, Kilbanski A, Neer M, Doppelt S H, Rosenthal D, Segre G V, et al. Increases in bone density during treatment of men with idiopathic hypogonadotrophic hypogonadism. J Clin Endocrinol Metab 1989; 69: 776–80
   PubMed Web of Science ®Google Scholar
• Behre H M, Kleish S, Leifke E, Link T M, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386–90
   PubMed Web of Science ®Google Scholar
• Morales A, Johnston B, Heaton J WP, Clark A. Oral androgens in the treatment of hypogonadal impotent men. J Urol 1994; 152: 1115–18
   PubMedGoogle Scholar
• Zamuda J M, Cauley J A, Kriska A. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle age men. A 13 year follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol 1997; 146: 609–14
   PubMed Web of Science ®Google Scholar
• Alexander P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996; 125: 1–4
   Google Scholar
• Phillips GB. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14: 701–5
   PubMed Web of Science ®Google Scholar
• Uyanik B S, Ari Z, Gumus B, Yigitoglu R, Arslan T. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly males. Jpn Heart J 1997; 38: 73–7
   PubMedGoogle Scholar
• Morley J E, Perry H M, Kaiser F E, Kraenzle D, Jensen J, Houston K, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1992; 41: 149–54
   Google Scholar
• Nieschlag E, Behre HM. Pharmacology and clinical uses of testosterone. Testosterone: Action, Deficiency, Substitution, E Nieschlag, HM Behre. Springer-Verlag, Berlin 1998; 294–321
   Google Scholar
• Tenover JL. Testosterone and the aging male. J Androl 1996; 18: 103–7
   Google Scholar
• Sternbach H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatry 1998; 155: 1310–15
   PubMed Web of Science ®Google Scholar
• Sourial N, Fenton F. Testosterone treatment of an XXYY male presenting with aggression: a case report. Can J Psychiatry 1998; 33: 846–7
   Google Scholar
• Christiansen K. Androgens, cognitive function and mood in men. Androgens and the Aging Male, B Oddens, A Vermeulen. Parthenon Publishing, CarnforthUK 1996; 147–65
   Google Scholar
• Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3587–91
   Web of Science ®Google Scholar
• Christiansen K. Behavioural correlates of testosterone. Testosterone: Action, Deficiency, Substitution, E Nieschlag, HM Behre. Springer-Verlag, Berlin 1998; 107–31
   Google Scholar
• Cheng E, Chung L, Grayhack J. Endocrinology of the prostate. Prostate Diseases, H Lepor, R K Lawson. WB Saunders, Philadelphia 1993; 57–71
   Google Scholar
• Meikle W A, Stephenson R A, Lewis C M, Middleton RG. Effects of age and sex hormones on transition and peripheral zone volumes in benign prostatic hyperplasia in twins. J Clin Endocrinol Metab 1997; 82: 571–5
   PubMed Web of Science ®Google Scholar
• Thomas J A, Keenan EJ. Effects of estrogens on the prostate. J Androl 1964; 15: 97–104
   Google Scholar
• Behre H M, Bohmeyer J, Nieschlag E. Prostate volume in treated and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol 1994; 40: 341–9
   PubMed Web of Science ®Google Scholar
• Douglas T H, Connelly R R, McLeod D G, Erickson S J, Barren R, III, Murphy G P. Effect of exogenous testosterone replacement on prostate specific antigen and prostate specific membrane antigen levels in hypogonadal men. J Surg Oncol 1995; 59: 246–9
   PubMed Web of Science ®Google Scholar
• Tenover IS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–6
   PubMed Web of Science ®Google Scholar
• Tenover JL. Androgen administration to aging men. Endocrinol Metab Clin North Am 1994; 23: 877–91
   PubMed Web of Science ®Google Scholar
• Vaughn D E, Cox DS. Chronic administration of dehydroepiandrosterone (DHEA) does not increase serum testosterone or prostatic specific antigen (PSA) in normal men [Abstr]. J Urol 1998; 159: 74
   Google Scholar
• Tenover JL. Androgen deficiency in aging men. Aging Male 1998; 1((Suppl 1))16
   Google Scholar
• Tenover JL. Androgen supplementation in hypogonadal elderly men. Presented at the Northeastern Section of the American Urological Association, Toronto, OntarioCanada, October, 17–211998
   Google Scholar
• Ross R, Bemstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young white and black men. J Natl Cancer Inst 1986; 76: 45–8
   PubMed Web of Science ®Google Scholar
• Jackson J A, Waman J, Spiekerman M. Prostatic complications of testosterone replacement therapy. Arch Intern Med 1989; 149: 2365–6
   PubMedGoogle Scholar
• Loughlin K R, Richie JP. Prostate cancer after exogenous testosterone treatment for impotence. J Urol 1997; 157: 1845
   PubMed Web of Science ®Google Scholar
• Curran M J, Bihrle W. Dramatic raise in prostate specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999; 53: 423–4
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Bruning C O, DeWolff WC. Occult prostate cancer in men with low serum testosterone levels. J Am Med Assoc 1996; 276: 1904–6
   PubMed Web of Science ®Google Scholar
• Hoffman M A, Morgentaler A, DeWolff W C. Free and total testosterone in the evaluation of prostate cancer: does low free testosterone predispose to more aggressive disease [Abstr]. J Urol 1999; 161: 321
   Google Scholar
• Shirai T, Imaida K, Masui T, Iwasaki S, Mori T, Kato T, et al. Effects of testosterone, dihydrotestosterone and estrogen on 3,2′-dimethyl-4-amino-biphenyl-induced rat prostate carcinogenesis. Int J. Cancer 1994; 57: 224–8
   PubMed Web of Science ®Google Scholar
• Noble RL. Development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977; 37: 1929–33
   PubMed Web of Science ®Google Scholar
• Nomura A, Heilrunn L K, Stemmermann G N, Judd HL. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1998; 48: 3515–18
   Google Scholar
• Cooper C S, Perry P J, Sparks A E, McIndoe J H, Yates W R, Williams RD. Effects of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 1998; 159: 441–3
   PubMed Web of Science ®Google Scholar
• Tenover JL. Androgen deficiency in the ageing male. Presented at the VI International Congress of Andrology, SalzburgAustria, May, 1997
   Google Scholar
• Durkan G C, Greene DR. Elevated serum prostate specific antigen levels in connection with an initial prostatic biopsy negative for carcinoma; who should undergo a repeat biopsy. Br J Urol Int 1999; 83: 34–8
   Google Scholar
• Nieschlag E, Wang C, Handelsman D J, Swerdloff R S, Wu F, Einer-Jensen N, et al. Guidelines for the Use of Androgens. World Health Organization, Geneva 1992
   Google Scholar
• Tremblay R R, Morales A. Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male 1998; 1: 213–18
   Google Scholar